Company Description
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy.
It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Country | Canada |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 3 |
CEO | Allen Davidoff |
Contact Details
Address: 3710 – 33rd Street NW Alberta Beach, AB T2L 2M1 Canada | |
Phone | (403) 455-7727 |
Website | xortx.com |
Stock Details
Ticker Symbol | XRTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001729214 |
CUSIP Number | 98420Q207 |
ISIN Number | CA98420Q3061 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Allen Warren Davidoff Ph.D. | Founder, Chief Executive Officer, President and Director |
James Neville Fairbairn C.A., C.P.A., ICD.D | Chief Financial Officer |
Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
Nick Rigopoulos | Director of Communications |
Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development |
Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
Charlotte May | Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 31, 2024 | D | Notice of Exempt Offering of Securities |
Oct 24, 2024 | 6-K | Report of foreign issuer |
Oct 18, 2024 | 6-K | Report of foreign issuer |
Oct 18, 2024 | 6-K | Report of foreign issuer |
Oct 18, 2024 | 6-K | Report of foreign issuer |
Oct 18, 2024 | 424B5 | Filing |
Oct 17, 2024 | 6-K | Report of foreign issuer |
Oct 17, 2024 | 424B5 | Filing |
Oct 9, 2024 | 6-K | Report of foreign issuer |
Sep 24, 2024 | 424B3 | Prospectus |